California and other states say the drugs are too costly, even as the Trump administration announces plans to lower prices.

People who took both Zepbound and an anti-inflammatory drug saw a greater improvement of their psoriatic arthritis symptoms.

These results tout the potential of the combination as the new standard of care (SoC) for PsA patients with comorbid obesity.

Eli Lilly said combining Taltz and Zepbound improved arthritis symptoms and drove meaningful weight loss, outperforming Taltz ...

Headache wasn’t reported as a side effect in Zepbound’s studies. But, it may be a symptom of some of Zepbound’s side effects. More common side effects of Zepbound are digestive side effects, such as ...

Retatrutide shows highest weight loss to date in trial Lilly says trial departures due to perceived excessive weight loss Retatrutide shows elevated skin-related side effects Dec 11 (Reuters) - Eli ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug. By Gina Kolata Gina Kolata has ...

Researchers from Macquarie University have published the world's first ever consensus-based recommendations on exercise as part of the management of lower limb lymphedema, a condition affecting ...

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The company still has a robust business that is delivering excellent results and ...

With a valid prescription, patients can access the starting dose of Zepbound single-dose vial (2.5 mg) for as low as $299 per month. “Far too many people who need obesity treatments still face cost ...

Eli Lilly on Monday announced new price cuts for its popular weight loss drug Zepbound, broadening access for patients and driving greater use of the company’s digital healthcare platform, LillyDirect ...

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up with rival Novo Nordisk A/S. Starting Monday, the lowest dose vial will cost ...